Search Results - "Zwerling, A. A"

GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis by Ling, D. I, Zwerling, A. A, Pai, M

“…The global extensively drug-resistant tuberculosis (TB) response plan calls for implementation of rapid tests to screen patients at risk of drug-resistant TB…”
Get full text

Tuberculosis screening costs and cost-effectiveness in high-risk groups: a systematic review by Alsdurf, H, Empringham, B, Miller, C, Zwerling, A

“…Systematic screening for active tuberculosis (TB) is a strategy which requires the health system to seek out individuals, rather than waiting for individuals…”
Get full text

How much does TB screening cost? A systematic review of economic evaluations by Empringham, B., Alsdurf, H., Miller, C., Zwerling, A.

“…BACKGROUND: Systematic screening for TB has been recommended as a method to control TB on a global level; however, this involves significant costs that place a…”
Get full text

Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review by Lai, Wendy A, Brethour, Kaitlyn, D'Silva, Olivia, Chaisson, Richard E, Zwerling, Alice A

“…We conducted a systematic review examining the cost effectiveness of a 3-month course of isoniazid and rifapentine, known as 3HP, given by directly observed…”
Get full text

Seven-year retrospective study understanding the latent TB infection treatment cascade of care among adults in a low incidence country by Sullivan, K, Pease, C, Zwerling, A, Mallick, R, Van Dyk, D, Mulpuru, S, Allen, C, Alsdurf, H, Alvarez, G.G

“…Abstract Background Prevention of TB is paramount to achieving elimination targets as recommended by the World Health Organization’s action framework for low…”
Get full text

Novel tests for diagnosing tuberculous pleural effusion: what works and what does not? by Trajman, A, Pai, M, Dheda, K, van Zyl Smit, R, Zwerling, A. A, Joshi, R, Kalantri, S, Daley, P, Menzies, D

“…Tuberculous pleuritis is a common manifestation of extrapulmonary tuberculosis and is the most common cause of pleural effusion in many countries. Conventional…”
Get full text

Building social equity and person-centred innovation into the end TB response by Engel, N., Apolosi, I., Bhargava, A., Bhan, A., Celan, C., Mak, A., Chikovore, J., Chorna, Y., Claassens, M.M., Dagron, S., Denholm, J.T., Frick, M., Furin, J., Hoddinott, G., Kashnitsky, D., Kielmann, K., Kunor, T., Lin, D., McDowell, A., Mitchell, E.M., Oga-Omenka, C., Samina, P., Shikoli, S.A., Silva, D.S., Stein, R., Stillo, J., van der Westhuizen, H.M., Wingfield, T., Zwerling, A., Daftary, A.

“…Reducing systemic inequities in testing, access to care, social protection - and in the scientific process - is essential to end TB. Incorporating social…”
Get full text

Effect of implementation of a 12-dose once-weekly treatment (3HP) in addition to standard regimens to prevent TB on completion rates: Interrupted time series design by Alvarez, Gonzalo G., Sullivan, Kathryn, Pease, Christopher, Van Dyk, Deborah, Mallick, Ranjeeta, Taljaard, Monica, Grimshaw, Jeremy M., Amaratunga, Kanchana, Allen, Crystal, Brethour, Kaitlyn, Mulpuru, Sunita, Pakhale, Smita, Aaron, Shawn D., Cameron, D. William, Alsdurf, Hannah, Hui, Charles, Zwerling, Alice A.

“…•3HP to treat LTBI is an alternative for TPT regular regimens•3HP significantly increases the proportion of patients completing TPT treatment•The use of 3HP in…”
Get full text

T-cell assay conversions and reversions among household contacts of tuberculosis patients in rural India by PAI, M, JOSHI, R, HOPEWELL, P. C, DOGRA, S, ZWERLING, A. A, GAJALAKSHMI, D, GOSWAMI, K, REDDY, M. V. R, KALANTRI, S, HILL, P. C, MENZIES, D

“…BACKGROUND: Interferon-gamma assays (IGRAs) are alternatives to the tuberculin skin test (TST), but IGRA conversions and reversions are not well understood. In…”
Get full text

ScreenTB: a tool for prioritising risk groups and selecting algorithms for screening for active tuberculosis by Miller, C. R., Mitchell, E. M. H., Nishikiori, N., Zwerling, A., Lönnroth, K.

“…SETTING AND OBJECTIVES: There is an urgent need to improve tuberculosis (TB) case detection globally. This would require greater focus on the implementation of…”
Get full text

Incorporating social justice and stigma in cost-effectiveness analysis: drug-resistant tuberculosis treatment by Zwerling, A., Dowdy, D., von Delft, A., Taylor, H., Merritt, M. W.

“…Novel therapies for multidrug-resistant tuberculosis (MDR-TB) are likely to be expensive. The cost of novel drugs (e.g., bedaquiline, delamanid) may be so…”
Get full text

Defining the research agenda to measure and reduce tuberculosis stigmas by Macintyre, K., Bakker, M. I., Bergson, S., Bhavaraju, R., Bond, V., Chikovore, J., Colvin, C., Craig, G. M., Cremers, A. L., Daftary, A., Engel, N., France, N. Ferris, Jaramillo, E., Kimerling, M., Kipp, A., Krishnaratne, S., Mergenthaler, C., Ngicho, M., Redwood, L., Rood, E. J. J., Sommerland, N., Stangl, A., van Rie, A., van Brakel, W., Wouters, E., Zwerling, A., Mitchell, E. M. H.

“…Crucial to finding and treating the 4 million tuberculosis (TB) patients currently missed by national TB programmes, TB stigma is receiving well-deserved and…”
Get full text

The implementation of rifapentine and isoniazid (3HP) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3HP study by Alvarez, G. G., Van Dyk, D., Mallick, R., Lesperance, S., Demaio, P., Finn, S., Potvin, S. Edmunds, Patterson, M., Pease, C., Amaratunga, K., Hui, C., Cameron, D.W., Mulpuru, S., Aaron, S.D., Momoli, F., Zwerling, A.

“…Background: The incidence of TB among Inuit is the highest in Canada. A significantly shorter latent TB infection (LTBI) treatment with rifapentine and…”
Get full text

Disadvantage and the experience of treatment for multidrug-resistant tuberculosis (MDR-TB) by Taylor, Holly A., Dowdy, David W., Searle, Alexandra R., Stennett, Andrea L., Dukhanin, Vadim, Zwerling, Alice A., Merritt, Maria W.

“…In the present research, we aimed to demonstrate how exploring patients’ treatment experiences may help decision makers better understand and pay attention to…”
Get full text

Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis by Gomez, G B, Dowdy, D W, Bastos, M L, Zwerling, A, Sweeney, S, Foster, N, Trajman, A, Islam, M A, Kapiga, S, Sinanovic, E, Knight, G M, White, R G, Wells, W A, Cobelens, F G, Vassall, A

“…Despite improvements in treatment success rates for tuberculosis (TB), current six-month regimen duration remains a challenge for many National TB Programmes,…”
Get full text

A simplified cost-effectiveness model to guide decision-making for shortened anti-tuberculosis treatment regimens by Zwerling, A., Gomez, G. B., Pennington, J., Cobelens, F., Vassall, A., Dowdy, D. W.

“…User-friendly models (UFMs) allow local decision makers to explore relationships and apply results from more detailed models of such outcomes as…”
Get full text

Predictive value of latent tuberculosis tests in Indian healthcare workers: a cohort study by Joshi, R, Narang, U, Zwerling, A, Jain, D, Jain, V, Kalantri, S, Pai, M

Get full text

Measuring Stigma to Assess the Social Justice Implications of Health-Related Policy Decisions: Application to Novel Treatment Regimens for Multidrug-Resistant Tuberculosis by Dowdy, David W., Zwerling, Alice A., Stennett, Andrea, Searle, Alexandra, Dukhanin, Vadim, Taylor, Holly A., Merritt, Maria W.

“…In making policy decisions with constrained resources, an important consideration is the impact of alternative policy options on social justice. Social justice…”
Get full text

Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis by Zifodya, Jerry S, Kreniske, Jonah S, Schiller, Ian, Kohli, Mikashmi, Dendukuri, Nandini, Schumacher, Samuel G, Ochodo, Eleanor A, Haraka, Frederick, Zwerling, Alice A, Pai, Madhukar, Steingart, Karen R, Horne, David J

“…Xpert MTB/RIF and Xpert MTB/RIF Ultra (Xpert Ultra) are World Health Organization (WHO)-recommended rapid tests that simultaneously detect tuberculosis and…”
Get more information

Diagnostics for tuberculosis: what new knowledge did we gain through The International Journal of Tuberculosis and Lung Disease in 2008? [Year in review] by MINION, J, ZWERLING, A, PAI, M

Get full text